Loading…
avatar for Theresa Sweeney

Theresa Sweeney

Nektar Therapeutics
Vice President, Safety Assessment
Dr. Sweeney is currently the Vice President of Safety Assessment at Nektar Therapeutics where she leads a team responsible for evaluating the safety of both large and small molecule drugs. She has more than 25 years of drug development experience at Nektar and Genentech. Her professional focus at Nektar has been on developing and implementing strategies for nonclinical safety development and authoring and defending nonclinical sections for regulatory submission. At Genentech, Dr. Sweeney was responsible for pulmonary drug delivery and focused on protein therapeutics and monoclonal antibodies for the treatment of pulmonary disease. Dr. Sweeney received her PhD from WVU and postdoctoral training at Harvard School of Public Health.